StockNews.com Begins Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

Equities research analysts at StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report issued on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Trading Down 26.0 %

TCON stock opened at $0.03 on Tuesday. The business’s 50 day moving average is $0.04 and its 200-day moving average is $0.27. The firm has a market cap of $109,802.00, a P/E ratio of 0.01 and a beta of 1.37. TRACON Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $14.75.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.